Cargando…
M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma
BACKGROUND: Sorafenib is the only approved first line systemic therapy for advanced hepatocellular carcinoma (HCC) in the last decade. Tumour resistance to sorafenib has been of major obstacles to improve HCC patient survival. METHODS: We polarised THP-1 cells to M1 and M2 macrophages, performed var...
Autores principales: | Dong, Ningning, Shi, Xiangyi, Wang, Suihai, Gao, Yanjun, Kuang, Zhenzhan, Xie, Qian, Li, Yonglong, Deng, Huan, Wu, Yingsong, Li, Ming, Li, Ji-Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738111/ https://www.ncbi.nlm.nih.gov/pubmed/31130723 http://dx.doi.org/10.1038/s41416-019-0482-x |
Ejemplares similares
-
Tspan5 promotes epithelial–mesenchymal transition and tumour metastasis of hepatocellular carcinoma by activating Notch signalling
por: Xie, Qian, et al.
Publicado: (2021) -
RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK–cyclin D1/CDK4 pathway
por: Wang, Suihai, et al.
Publicado: (2019) -
Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019) -
MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis
por: Li, Yue, et al.
Publicado: (2017) -
Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)